csanctuary

csanctuary's picture

Colin Sanctuary

QGel

Member Profile: 

Colin co-founded QGel in 2009 and was appointed CEO by the Board of Directors to oversee the establishment of the company.

Colin did his undergraduate studies at McGill University in Canada, and Chalmers Tekniska Högskolan in Sweden. He obtained his PhD in 2003 at the Swiss Federal Institute of Technology (EPFL).

After his PhD, Colin held various management positions starting at Straumann, a dental implant company, where as Product Manager he was globally responsible for regenerative products. Before starting QGel, Colin was a manager at Medtronic where he managed the biologics product portfolio across Europe.

 

Company Profile: 

QGel is an early-stage start up and a spin-off from the EPFL founded in July 2009. In mid-2010, QGel launched a hydrogel that is a synthetic copy of collagen that allows you to grow complex tissue and shapes without the need for animal hosts.

Simple to use both manually and with liquid-handling robots, QGel is used by pharmaceutical companies as a 3D matrix to grow tissue from cells of all types, particularly for stem cells and cancer cells. These new 3D cell-based assays allow them to screen their compound libraries more effectively, and to improve their drug development process.

Other QGel customers use our technology for molecular screening in the field of personalized medicine. By growing cancer cells from patients in QGel, physicians can identify the right chemotherapy treatment for a specific cancer patient.

 

Member nationality: 
Canada
Company nationality: 
Switzerland
Company industry sector: 
Health/Life Sciences